Earnings Summary

Biomarin Pharmaceutical Inc.’s revenue jumped 19.18% since last year same period to $708.66Mn in the Q2 2024. On a quarterly growth basis, Biomarin Pharmaceutical Inc. has generated 9.22% jump in its revenue since last 3-months.

Biomarin Pharmaceutical Inc.’s net profit jumped 91.25% since last year same period to $107.17Mn in the Q2 2024. On a quarterly growth basis, Biomarin Pharmaceutical Inc. has generated 20.88% jump in its net profits since last 3-months.

Biomarin Pharmaceutical Inc.’s net profit margin jumped 60.46% since last year same period to 15.12% in the Q2 2024. On a quarterly growth basis, Biomarin Pharmaceutical Inc. has generated 10.67% jump in its net profit margins since last 3-months.

Biomarin Pharmaceutical Inc.’s price-to-earnings ratio after this Q2 2024 earnings stands at 52.63.

Biomarin Pharmaceutical Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.52 - a 48.57% jump from last quarter’s estimates.

Biomarin Pharmaceutical Inc.’s earning per share (EPS) estimates for the current year stand at 0.52.

Biomarin Pharmaceutical Inc.’s earning per share (EPS) jumped 93.1% since last year same period to 0.56 in the Q2 2024. This indicates that the Biomarin Pharmaceutical Inc. has generated 93.1% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Biomarin Pharmaceutical Inc.’s return on assets (ROA) stands at 0.02.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Biomarin Pharmaceutical Inc.’s return on equity (ROE) stands at 0.05.